Publications by authors named "Bery Mohammediyan"
Background: Amyloid-negative tau-positive PET (A-T+) participants have been reported in several studies. We assessed the prevalence and characteristics of A-T+ participants in a cohort of cognitively unimpaired individuals with a first-degree family history of Alzheimer's disease (AD) dementia.
Method: We studied 252 participants from the longitudinal PREVENT-AD cohort (mean cognitive follow-up = 3.
Background: Increasing evidence suggests a link between sleep and Alzheimer disease's (AD) pathology and cognitive decline. We investigated whether sleep disturbances might be accompanied by faster AD pathology accumulation and/or cognitive decline before the onset of cognitive symptoms.
Method: We investigated cross-sectional and longitudinal associations between sleep quality, AD pathology and cognition in 220 participants from the PREVENT-AD cohort.
Background: Amyloid-negative tau-positive PET (A-T+) participants have been reported in several studies. We assessed the prevalence and characteristics of A-T+ participants in a cohort of cognitively unimpaired individuals with a first-degree family history of Alzheimer's disease (AD) dementia.
Method: We studied 252 participants from the longitudinal PREVENT-AD cohort (mean cognitive follow-up = 3.
Study Objectives: Although short sleep could promote neurodegeneration, long sleep may be a marker of ongoing neurodegeneration, potentially as a result of neuroinflammation. The objective was to evaluate sleep patterns with age of expected Alzheimer's disease (AD) onset and neuroinflammation.
Methods: We tested 203 dementia-free participants (68.
Day-to-day sleep variability with Alzheimer's biomarkers in at-risk elderly.
Alzheimers Dement (Amst)
February 2024
Introduction: Measuring day-to-day sleep variability might reveal unstable sleep-wake cycles reflecting neurodegenerative processes. We evaluated the association between Alzheimer's disease (AD) fluid biomarkers with day-to-day sleep variability.
Methods: In the PREVENT-AD cohort, 203 dementia-free participants (age: 68.